Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SC-1 是一种 Sorafenib 的衍生物,可抑制 STAT3磷酸化,通过依赖 SHP-1 的 STAT3失活诱导细胞凋亡,具有抗癌作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,150 | 现货 | ||
5 mg | ¥ 2,470 | 现货 | ||
10 mg | ¥ 3,890 | 现货 | ||
25 mg | ¥ 6,900 | 现货 | ||
50 mg | ¥ 9,790 | 现货 | ||
100 mg | ¥ 12,900 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,820 | 现货 |
产品描述 | SC-1 is a a derivative of the multiple tyrosine kinase inhibitor sorafenib. SC-1 potently inhibits the phosphorylation of STAT3 by blocking STAT3 phosphorylation and activation, and induces apoptosis in hepatocellular carcinoma cell lines[1]. |
体外活性 | SC-1(1-10 μM; 48 hours; breast cancer cells) treatment demonstrates dose-dependent suppression of cell viability in all tested breast cancer cells[1]. SC-1(1-10 μM; 36 hours; breast cancer cells) treatment induces potent apoptotic activity in association with downregulation of p-STAT3 and its downstream proteins cyclin D1 and survivin in a dose-dependent manner in breast cancer cell lines[1]. |
体内活性 | SC-1 showes efficacious antitumor activity and p-STAT3 downregulation in MDA-MB-468 xenograft tumors in vivo[1]. |
细胞实验 | Incubated HCC-1937, MDA-MB-231, MDA-MB-468, MDA-MB-453, SK-BR3 and MCF-7 cells with 1 μM, 2 μM, 5 μM, 7.5 μM, 10 μM SC-1 for 48 hours demonstrated that dose-dependent suppression of cell viability in all tested breast cancer cells[1]. Incubated HCC-1937, MDA-MB-231, MDA-MB-468, MDA-MB-453, SK-BR3 and MCF-7 cells with 1 μM, 2 μM, 5 μM, 7.5 μM, 10 μM SC-1 for 36 hours showed downregulation of p-STAT3 and its downstream proteins cyclin D1 and survivin in a dose-dependent manner in breast cancer cell lines and induced potent apoptotic activity[1]. |
动物实验 | SC-1 (10 mg/kg; oral gavage; daily; for 28 days; Female NCr athymic nude mice (4-6 weeks of age) injected with breast cancer cells) treatment shows efficacious antitumor activity and p-STAT3 downregulation in MDA-MB-468 xenograft tumors[1]. |
分子量 | 431.8 |
分子式 | C21H13ClF3N3O2 |
CAS No. | 1313019-65-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (127.37 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3159 mL | 11.5794 mL | 23.1589 mL | 57.8972 mL |
5 mM | 0.4632 mL | 2.3159 mL | 4.6318 mL | 11.5794 mL | |
10 mM | 0.2316 mL | 1.1579 mL | 2.3159 mL | 5.7897 mL | |
20 mM | 0.1158 mL | 0.579 mL | 1.1579 mL | 2.8949 mL | |
50 mM | 0.0463 mL | 0.2316 mL | 0.4632 mL | 1.1579 mL | |
100 mM | 0.0232 mL | 0.1158 mL | 0.2316 mL | 0.579 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea 1313019-65-6 Apoptosis JAK/STAT signaling Stem Cells STAT cyclin-D1 Inhibitor inhibit kinase 1(4Chloro3(trifluoromethyl)phenyl)3(4(4cyanophenoxy)phenyl)urea p-STAT3 orally anticancer SHP-1 1 (4 Chloro 3 (trifluoromethyl)phenyl) 3 (4 (4 cyanophenoxy)phenyl)urea survivin inhibitor